Con­sor­tium of 5 drug reg­u­la­tors plot path to in­crease har­mo­niza­tion through 2024

A group of drug reg­u­la­tors from Aus­tralia, Cana­da, Sin­ga­pore, Switzer­land and the UK on Tues­day un­veiled their strate­gic plans for the next three years, lay­ing out how they’ll work to­geth­er on re­view­ing new drugs to re­duce du­pli­ca­tion across bor­ders.

While un­der­stand­ing that the bio­phar­ma in­dus­try is tru­ly glob­al, the group, known col­lec­tive­ly as the Ac­cess Con­sor­tium, seeks to bet­ter align their re­spec­tive reg­u­la­to­ry and pol­i­cy ap­proach­es for phar­ma­ceu­ti­cals, with an aim to fa­cil­i­tate faster ac­cess to high qual­i­ty, safe and ef­fec­tive health prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER